Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Q2 2025 value amounting to $113000.0.

  • Corvus Pharmaceuticals' Capital Expenditures changed N/A to $113000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year change of. This contributed to the annual value of $34000.0 for FY2023, which is 8736.06% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Capital Expenditures stood at $113000.0 for Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Capital Expenditures ranged from a high of $265000.0 in Q3 2022 and a low of $34000.0 during Q1 2023
  • Over the past 3 years, Corvus Pharmaceuticals' median Capital Expenditures value was $74500.0 (recorded in 2025), while the average stood at $112000.0.